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ABSTRACT
Chronic rhinosinusitis is a heterogeneous disease. In Europe and the United States, it has recently been di-
vided into two subgroups: chronic rhinosinusitis with nasal polyps (CRSwNP) and chronic rhinosinusitis without
nasal polyps (CRSsNP). The majority of CRSwNP cases have a strong tendency to recur after surgery and
show eosinophil-dominant inflammation. However, this definition has proved difficult to apply in Japan and East
Asia, because more than half of the CRSwNP cases do not exhibit eosinophil-dominant inflammation in these
areas of the world. In Japan in the 1990s, refractory CRSwNP to the standard treatment was focused on in
clinical studies and the term “eosinophilic chronic rhinosinusitis” (ECRS) was introduced to identify this sub-
group of chronic rhinosinusitis in 2001.
ECRS is different from non-ECRS in terms of many clinical features: symptom appearance, occurrence site
of nasal polyps, CT scan findings, the histology of nasal polyps, blood examination findings, clinical course af-
ter surgery, and co-morbid asthma, etc. In this review, we describe these clinical features and mention how to
make a clinical diagnosis of ECRS as well as how to treat it. Finally, we discuss the pathophysiology of ECRS.
The concept of ECRS in Japan would be applicable for CRSwNP in other countries including Europe and the
United States.
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INTRODUCTION
The term chronic sinusitis is usually used for chronic
inflammation of the paranasal sinus in Japan. How-
ever, because most cases of chronic sinusitis have a
proceeding or concomitant involvement of the nasal
cavity, and because the term chronic rhinosinusitis is
more common in English papers rather than the term
chronic sinusitis, the term chronic rhinosinusitis is
used in this review.
Although chronic rhinosinusitis is a very common
and heterogeneous disease, there are many unsolved
issues surrounding its pathophysiology, subclassifica-
tion, and treatment. While many studies have tried to
subclassify chronic rhinosinusitis based on its patho-
physiology, a clear definition that can distinguish
each subgroup of the disease has not yet been estab-
lished. In Europe and the United States, chronic rhi-
nosinusitis has been recently divided into two sub-
groups: chronic rhinosinusitis with polyps (CRSwNP)
and chronic rhinosinusitis without polyps
(CRSsNP).1,2 In CRSwNP patients, there is a strong
tendency for recurrence after surgery and a pro-
nounced presence of both eosinophils and
interleukin-5 (IL-5) in the nasal polyps.2 This defini-
tion is simple and convenient for use in clinical stud-
ies and clinical practice, but it has proved difficult to
apply in Japan and in East Asia (Korea and southern
China).3-6 In these areas, more than half of the
CRSwNP cases do not exhibit eosinophil-dominant in-
flammation. Therefore, another definition for discus-
sion of heterogeneity of chronic rhinosinusitis may
be necessary in East Asia. Moreover, chronic rhinosi-
nusitis is often associated with lower respiratory dis-
eases. The association between chronic rhinosinusitis
and asthma is clinically important.
HETEROGENEITY OF CHRONIC RHINOSI-
NUSITIS
Chronic rhinosinusitis is defined as chronic inflam-
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Fig. 1 Cytology of nasal secretions.
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mation of sinonasal mucosa and characterized by
presence of two or more common nasal symptoms in-
cluding nasal discharge, nasal obstruction, post nasal
drip and reduction in or loss of the sense of smell.
The diagnosis of chronic rhinosinusitis is based on
these symptoms lasting longer than 3 months and si-
nus opacification in plain sinus x-ray or CT scan.
Chronic rhinosinusitis is a heterogeneous disease
and patients exhibit various signs and symptoms. The
variety of nasal secretions, for example, includes
serous, mucous, purulent and very viscous. Inflam-
matory cells in nasal secretions are also heterogene-
ous. Figure 1 shows cytology of nasal secretions. Na-
sal secretions of some patients contain many neutro-
phils while others contain degraded eosinophils. It is
suspected that the former is neutrophilic inflamma-
tion and the latter is eosinophilic inflammation. The
opacification pattern of sinus imaging is also hetero-
geneous. If we compare the degree of opacification of
the maxillary and ethmoid sinus, some patients show
ethmoid sinus-dominant opacification while others
show maxillary sinus-dominant opacification. If the
disease condition becomes more severe, both types
of patients exhibit pan-sinusitis pattern. Figure 2 indi-
cates different sinus opacification patterns.
Low-dose and long-term administration of macrol-
ide antibiotics (macrolide therapy) is basic treatment
for chronic rhinosinusitis in Japan, and response of
patients with chronic rhinosinusitis to macrolide ther-
apy is also heterogeneous. Macrolide therapy was
discovered in Japan as a treatment for diffuse pan-
bronchitis (DPB),7 and in the late 1980s was shown
to be effective for chronic rhinosinusitis associated
with DPB.8 Then, macrolide therapy was proven to
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Table 1 Comparison between ECRS and non-ECRS
Non-Eosinophilic Chronic Rhinosinusitis 
(non-ECRS)
Eosinophilic Chronic Rhinosinusitis 
(ECRS)
(usual)reduction/loss of smel in early stagesCharacteristic symptoms
mucopurulent discharge,
nasal polyp in middle meatus
bilateral polyps, high viscous secretionEndonasal findings
maxilary predominance (in early stages)ethmoid predominance (in early stages)CT findings
-eosinophiliaBlood examination
less-frequentfrequentCoexistence of asthma
efectivenot efectiveMacrolide therapy
lowvery highRecurent rate of nasal polyps
unclearhigher eficacySystemic steroid for recurence
lymphocyte infiltration, nasal grand 
increase
eosinophilia, lymphocyte infiltration, 
basement membrane thickening
 (remodeling)
Histology of nasal polyps
be an effective therapy for chronic rhinosinusitis
without DPB.9 In Japan in the 1990s, macrolide ther-
apy was considered to be the first line of treatment,
and the combination of macrolide therapy and newly
developed endoscopic sinus surgery (ESS) was the
gold standard for chronic rhinosinusitis treat-
ment.10,11 After it became possible to successfully im-
prove most chronic rhinosinusitis, understanding of
the clinical and histological features of refractory
types of the disease in response to this combined
therapy has progressed. As one of the features associ-
ated with the affliction is abundant eosinophil infiltra-
tion in nasal polyps,12 the term eosinophilic chronic
rhinosinusitis (ECRS) was introduced to identify this
subgroup of chronic rhinosinusitis in Japan in 2001.13
In this review, chronic rhinosinusitis with nasal pol-
yps (CRSwNP) is discussed, and the terms ECRS and
non-ECRS as a subgroup of CRSwNP are described in
the following sections. In Japan, non-ECRS had been
the most common type of CRSwNP up until 30 years
ago, and nasal polyps of non-ECRS do not exhibit
abundant eosinophil infiltration. Patients with non-
ECRS exhibit purulent nasal discharge containing
neutrophils, and its inflammation is assumed to be
non-eosinophilic.
CLINICAL FEATURES OF EOSINOPHILIC
CHRONIC RHINOSINUSITIS (ECRS)
As ECRS was recognized as refractory chronic rhi-
nosinusitis despite combination of macrolide therapy
and ESS in Japan,13 one of the most characteristic
clinical features is a strong tendency for recurrence
after ESS. Clinical features of ECRS are listed in Ta-
ble 1 in comparison with non-ECRS.
SYMPTOMS
While a common symptom of ECRS patients is nasal
congestion, reduction in or loss of the sense of smell
precedes nasal congestion in many cases of the pa-
tients. This smell disorder that appears early in the
illness is characteristic for ECRS as compared to non-
ECRS. ECRS patients may exhibit other nasal symp-
toms including nasal discharge, postnasal drip, facial
pressure, or headache. Nasal discharge of ECRS pa-
tients is usually not purulent.
NASAL POLYPS
While nasal polyps are raised from the middle meatus
in most non-ECRS patients, ECRS patients can ex-
hibit bilateral nasal polyps that are often found in
both the middle meatus and inside of the middle tur-
binate. This could explain why ECRS patients com-
plain of smell disorder early in the illness.
CT SCAN FINDINGS
It has been previously reported that CT scan images
of ECRS patients show ethmoid sinus-dominant
opacification.3 In our recent study, it was found that
all CT scores of sinuses, except for the maxillary si-
nus, were significantly different between ECRS and
non-ECRS. The most apparent differences in CT im-
ages of ECRS compared to non-ECRS images was in-
volvement of the posterior ethmoid sinus. CT images
from the early stage of ECRS can show opacification
of posterior ethmoid sinus and the olfactory cleft.
The middle meatus or ostiomeatal complex (OMC)
has been demonstrated to have a fundamental role in
the pathogenesis of non-ECRS.2 If drainage from the
sinus to middle meatus or OMC is impaired, the si-
nus becomes secondarily involved. According to this
pathogenesis, sinuses that are most likely to be af-
fected are maxillary sinus and anterior ethmoid sinus.
These sinuses connect to the middle meatus or OMC
through small ostia. In ECRS patients, however, pos-
terior ethmoid sinuses that do not directly connect
with the middle meatus are involved in similar to an-
terior ethmoid sinuses even in the early stage. This
suggests that pathological changes in middle meatus
or OMC might be of less importance for the patho-
genesis of ECRS. Namely, the pathogenesis of ECRS
is different from that of non-ECRS. Opacification of
the olfactory cleft is also characteristics for ECRS.
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Fig. 3 Histology of nasal polyps.
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Fig. 4 Corelation between peripheral blood eosinophils 
and infiltrated eosinophils in nasal polyps.
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This pathological change may exhibit smell disorder
in the early stage of ECRS.
HISTOLOGY OF NASAL POLYPS
Histological findings of nasal polyps reveal most char-
acteristic features of ECRS. Figure 3 demonstrates
massive infiltration of eosinophils in lamina propria, a
thick basement membrane, and increased goblet
cells. These findings are similar to the remodeling of
bronchial mucosa in asthmatic patients.14 This mas-
sive tissue eosinophilia is a reason why this type of
CRSwNP is called eosinophilic chronic rhinosinusitis
in Japan. Most infiltrating inflammatory cells in nasal
polyps in non-ECRS are lymphocytes (plasma cells)
(Fig. 3). Even though most inflammatory cells in na-
sal polyps are lymphocytes, nasal smear cytology of
non-ECRS patients shows neutrophilic inflammation.
BLOOD EXAMINATION
Peripheral blood eosinophilia is a characteristic blood
finding for ECRS. Peripheral blood eosinophil counts
significantly correlate with infiltrating eosinophil
counts in nasal polyps (Fig. 4). Therefore, peripheral
blood eosinophilia is of diagnostic value for ECRS.
There is no other routine blood examination which
indicates ECRS. Some ECRS patients show total or
specific IgE elevation, but more than half of ECRS pa-
tients do not exhibit an atopic condition.
CLINICAL COURSE
A tendency for recurrence after ESS despite macrol-
ide therapy is of diagnostic value for ECRS.15 Even if
there are no recurrent nasal polyps, after surgery
ECRS patients often exhibit edematous changes of si-
nonasal mucosa in proximity to the middle turbinate.
Regardless of such strong tendency of recurrence,
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Table 2 Practical diagnosis for eosinophilic chronic rhinosinusitis
(1) Clinical history
・Nasal symptoms of chronic rhinosinusitis
・Reduction and/or loss of smel in the early stages
(2) Endonasal examination
・Bilateral polyps (polyposis)
・High viscous secretion
(3) Clinical examinations 
・Peripheral blood eosinophilia
・CT findings (Ethmoid sinus dominant opacification)
4. Histological findings
・Massive eosinophilic infiltration in nasal polyps
5. Postoperative course
・Strong tendency to recur after ESS
・Efectiveness of systemic steroid for treatment of recurence
nasal symptoms of ECRS patients who have under-
gone ESS are usually well controlled with adequate
postoperative treatment described in the following
section.
These clinical features resemble CRSwNP (nasal
polyposis) as defined in Europe and the United
States. In 1995, Klapan and Culo reported that the in-
cidence of polyposis recurrence was significantly
higher in patients with increased LTC4 level in nasal
polyps.16 Because the CysLTs level in nasal polyps is
an indicator for severity of eosinophilic inflamma-
tion,17 the tendency for recurrence after surgery may
be related to the severity of eosinophilic inflamma-
tion.
CO-MORBID ASTHMA
Asthma co-morbidity is often seen in ECRS. The se-
verity of asthma which is associated with ECRS is
usually moderate to severe, and most patients with
chronic rhinosinusitis associated with aspirin-
intolerant asthma have ECRS. If patients with chronic
rhinosinusitis have non-atopic asthma, ECRS might
be suspected. However, because about half of ECRS
is not associated with asthma, co-morbidity with
asthma may not be a diagnostic criterion for ECRS.15
Even if ECRS patients do not present with asthma,
most exhibit airway hyper-responsiveness.18 This
suggests that such ECRS patients are at high risk for
developing asthma.
CLINICAL DIAGNOSIS FOR ECRS
A clear definition of and diagnostic criteria for ECRS
have still not been established in Japan, Europe, or
the United States. However, consensus for clinical di-
agnosis of ECRS is now building in Japan. It is not dif-
ficult to diagnose ECRS with the combination of sev-
eral clinical features as mentioned above (Table 1).
Among them, a strong tendency to recur after ESS
could be very important. However, this criterion can-
not be used for patients who do not undergo surgery.
How to diagnose ECRS precisely with usual clinical
diagnostic tools was studied, and the combination
both CT findings and peripheral blood eosinophilia
achieved high diagnostic value. If peripheral blood
eosinophilia and CT scoring for both posterior eth-
moid and olfactory cleft are used as diagnostic crite-
ria, sensitivity and specificity for diagnosis of ECRS
are very high. Furthermore, if other clinical features
are also taken into consideration in addition to these
criteria (Table 2), accurate clinical diagnosis of ECRS
could be made in an outpatient clinic.
TREATMENT FOR ECRS
ECRS is refractory to conservative medical manage-
ment. Systemic steroids reduce nasal symptoms of
ECRS. However, it is difficult to improve such symp-
toms completely and to maintain a good condition for
a long time. Therefore, surgical treatment (ESS) is an
important first-line treatment.15 The purpose of the
surgery is not only to remove the nasal polyps but
also to open sinuses widely to enhance the effect of
post-operative maintenance therapy. Such post-
operative therapy is very important for control of
chronic sinonasal inflammation.
The post-operative maintenance therapy includes
nasal irrigation, intranasal steroid administration, and
oral anti-allergic medicine (anti-leukotrienes). Nasal
irrigation and intranasal steroids are basic treat-
ments, and oral medicines are added according to na-
sal condition of patients as needed. Nasal irrigation is
thought to wash out microorganisms and chemical
mediators, inducing eosinophilic inflammation like
CysLTs and IL-5. If nasal polyps recur despite these
maintenance therapies, a relatively high dose of oral
steroid (0.5 mgkg) for 1 or 2 weeks is very effective
to cause recurrent nasal polyps to disappear.
While treatment that can bring complete relief of
symptoms with ECRS has not yet been established,
an adequate combination of surgery and post-
operative therapy can maintain a good condition in
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most ECRS patients.
PATHOPHYSIOLOGY OF ECRS
The pathophysiology of ECRS is still unknown. Be-
cause most CRSwNP in Europe and the United States
seems to correspond to ECRS in Japan, many studies
for CRSwNP are of great help in discussing the patho-
physiology of ECRS in Japan.
A primary question surrounding the pathophysiol-
ogy of ECRS is the mechanism that induces marked
eosinophilic inflammation of sinonasal mucosa. The
approach to consider this question can be roughly di-
vided in two ways: activation eosinophils and im-
paired suppression of aggravated inflammation.
Eosinophil counts are significantly higher in nasal
polyps of ECRS compared to non-ECRS, but that is in-
dependent from atopic status. Some patients with
ECRS have IgE specific to common inhalant antigens,
but atopic status is not always the case.
Many of the following inflammatory mediators
have been reported to be related to eosinophilic in-
flammation in sinonasal mucosa including cytokines
(IL-519 and GM-CSF20), chemokines (eotaxins21) and
chemical mediator (CysLTs22). Because eotaxin is
produced from epithelial cells and fibroblasts, non-
specific stimuli could induce eosinophilic inflamma-
tion by stimulating these cells.
Bachert et al.23 reported correlations between IgE
specific to a variety of allergens including Staphylococ-
cus aureus enterotoxins and eosinophilic inflamma-
tion in nasal polyps of non-atopic patients. Recently,
Sheahan et al.24 showed that more than half of
CRSwNP polyps demonstrated a polyclonal IgE re-
sponse in sinonasal mucosa and suggested that local
mucosal IgE specific to common inhalant allergens
play an important role for eosinophilic inflammation
even in non-atopic CRSwNP patients. Namely, locally
produced IgE by Staphylococcus aureus enterotoxins
or other inhalant allergens could induce eosinophilic
inflammation of sinonasal mucosa independently with
systemic atopy.
In the United States, fungi have received much at-
tention as candidates for inducing ECRS and allergic
fungal rhinosinusitis (AFRS, a subgroup of ECRS).25
Diagnostic criteria for AFRS include type 1 hypersen-
sitivity to fungi, nasal polyposis, and eosinophilic mu-
cin containing fungal elements.26 Although there is
considerable overlap in findings between AFSR and
ECRS, the clinical features of AFRS are different from
ECRS. In Japan, AFRS is relatively rare compared to
ECRS; therefore, the comparison between them is
not discussed further in this article.
Fungi have also been postulated to be a trigger for
eosinophilic inflammation of sinonasal mucosa even
in patients who do not have type l hypersensitivity to
fungi.27 There is a report that suggests non-atopic
eosinophilia or local IgE production by fungi in si-
nonasal mucosa.28 However, if more sensitive diag-
nostic techniques are used, fungi could be detected
in the nasal passages of not only patients with ECRS
but also in normal controls. Fungi could be important
in the pathophysiology of ECRS, but further studies
are necessary.
CONCLUSION
ECRS is a subgroup of CRSwNP in Japan. Although a
consensus surrounding diagnosis and treatment for
ECRS has been building, a clear definition should be
established in the near future, and diagnostic criteria
based on these criteria should follow. Moreover, be-
cause the heterogeneous presentation of chronic rhi-
nosinusitis in Japan and East Asia is different from
that in Europe and the United States, a global consen-
sus for subclassification of chronic rhinosinusitis
should be discussed.
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